Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 28, 2017; 23(48): 8512-8525
Published online Dec 28, 2017. doi: 10.3748/wjg.v23.i48.8512
Published online Dec 28, 2017. doi: 10.3748/wjg.v23.i48.8512
Figure 9 Astragaloside IV abolished the GCAF-induced up-regulation of SOX2 and NANOG in BGC-823 cells.
BGC-823 cells were cultured with conditioned media from the GNFs, GCAFs, control-treated GCAFs or 40 μmol/L astragaloside IV-treated GCAFs. Then, the mRNA (A) and protein (B) expression of SOX2 and NANOG were determined. Data are plotted as mean ± SD of three separate experiments. bP < 0.01.
- Citation: Wang ZF, Ma DG, Zhu Z, Mu YP, Yang YY, Feng L, Yang H, Liang JQ, Liu YY, Liu L, Lu HW. Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts. World J Gastroenterol 2017; 23(48): 8512-8525
- URL: https://www.wjgnet.com/1007-9327/full/v23/i48/8512.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i48.8512